New Clot-Busting drug could change heart attack care

NCT ID NCT06769256

Recruiting now Disease control Sponsor: Henan Institute of Cardiovascular Epidemiology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two drugs given directly into the heart arteries during a heart attack: rhTNK-tPA, a clot dissolver, and tirofiban, a blood thinner. Researchers will enroll 300 patients with severe blockages to see which drug restores blood flow better and causes fewer bleeding problems. The goal is to find a safer, more effective way to treat heart attacks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rhTNK-tPA (a clot-dissolving drug) and tirofiban (a blood-thinning drug)
What this could lead to: If rhTNK-tPA works as well as tirofiban, it could offer another option to restore blood flow after a heart attack, potentially reducing heart damage.
What could go wrong: This is a mid-stage trial with only 300 patients, so results may not apply to everyone. Both drugs carry a risk of bleeding, and rhTNK-tPA might not prove as effective or safe as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

Contacts and locations

Locations

Fuwai Central China Cardiovascular Hospital
RECRUITING

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.